Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer

The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old, have championed the potential for immunotherapy for over a century. Finally, advances in our understanding of the fundamentals of tumor immunology are translating into clinical success, w...

Full description

Bibliographic Details
Main Authors: Page, David B., Bourla, Ariel Bulua, Daniyan, Anthony, Naidoo, Jarushka, Smith, Eric, Smith, Melody, Friedman, Claire, Khalil, Danny N., Funt, Samuel, Shoushtari, Alexander N., Overwijk, Willem W., Sharma, Padmanee, Callahan, Margaret K.
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469248/
id pubmed-4469248
recordtype oai_dc
spelling pubmed-44692482015-06-17 Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer Page, David B. Bourla, Ariel Bulua Daniyan, Anthony Naidoo, Jarushka Smith, Eric Smith, Melody Friedman, Claire Khalil, Danny N. Funt, Samuel Shoushtari, Alexander N. Overwijk, Willem W. Sharma, Padmanee Callahan, Margaret K. Meeting Report The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old, have championed the potential for immunotherapy for over a century. Finally, advances in our understanding of the fundamentals of tumor immunology are translating into clinical success, with recent US Food and Drug Administration approval of several immunotherapies that improve clinical outcomes across prostate cancer, metastatic melanoma, non-small cell lung cancer and lymphocytic leukemia. In tandem with these clinical successes, new technologies such as high-throughput DNA/RNA sequencing, genetic engineering, and streamlined ex vivo cell culturing have paved the way for the next generation of immunotherapies and provided new tools for investigating potential biomarkers of response to existing therapies. During the November 2014 Annual Meeting of the Society of the Immunotherapy of Cancer, leaders in tumor immunology and cancer immunotherapy convened at the second annual SITC Primer to review both current knowledge and future directions in the field. Here, we will review the key discussions across a variety of topics, including innate immunity, adaptive immunity, dendritic cells, adoptive T cell therapy, anti-tumor antibodies, cancer vaccines, immune checkpoint blockade, challenges to immunotherapy, monitoring immune responses, and immunotherapy clinical trial design. BioMed Central 2015-06-16 /pmc/articles/PMC4469248/ http://dx.doi.org/10.1186/s40425-015-0072-2 Text en © Page et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Page, David B.
Bourla, Ariel Bulua
Daniyan, Anthony
Naidoo, Jarushka
Smith, Eric
Smith, Melody
Friedman, Claire
Khalil, Danny N.
Funt, Samuel
Shoushtari, Alexander N.
Overwijk, Willem W.
Sharma, Padmanee
Callahan, Margaret K.
spellingShingle Page, David B.
Bourla, Ariel Bulua
Daniyan, Anthony
Naidoo, Jarushka
Smith, Eric
Smith, Melody
Friedman, Claire
Khalil, Danny N.
Funt, Samuel
Shoushtari, Alexander N.
Overwijk, Willem W.
Sharma, Padmanee
Callahan, Margaret K.
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
author_facet Page, David B.
Bourla, Ariel Bulua
Daniyan, Anthony
Naidoo, Jarushka
Smith, Eric
Smith, Melody
Friedman, Claire
Khalil, Danny N.
Funt, Samuel
Shoushtari, Alexander N.
Overwijk, Willem W.
Sharma, Padmanee
Callahan, Margaret K.
author_sort Page, David B.
title Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
title_short Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
title_full Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
title_fullStr Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
title_full_unstemmed Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
title_sort tumor immunology and cancer immunotherapy: summary of the 2014 sitc primer
description The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old, have championed the potential for immunotherapy for over a century. Finally, advances in our understanding of the fundamentals of tumor immunology are translating into clinical success, with recent US Food and Drug Administration approval of several immunotherapies that improve clinical outcomes across prostate cancer, metastatic melanoma, non-small cell lung cancer and lymphocytic leukemia. In tandem with these clinical successes, new technologies such as high-throughput DNA/RNA sequencing, genetic engineering, and streamlined ex vivo cell culturing have paved the way for the next generation of immunotherapies and provided new tools for investigating potential biomarkers of response to existing therapies. During the November 2014 Annual Meeting of the Society of the Immunotherapy of Cancer, leaders in tumor immunology and cancer immunotherapy convened at the second annual SITC Primer to review both current knowledge and future directions in the field. Here, we will review the key discussions across a variety of topics, including innate immunity, adaptive immunity, dendritic cells, adoptive T cell therapy, anti-tumor antibodies, cancer vaccines, immune checkpoint blockade, challenges to immunotherapy, monitoring immune responses, and immunotherapy clinical trial design.
publisher BioMed Central
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469248/
_version_ 1613236294696042496